Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis
30 mai 2024 08h00 HE
|
Olink Proteomics AB
Landmark study using the Olink Explore platform identifes proteins in the blood that may provide a 7-year warning for various cancers.
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
30 mai 2024 08h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Promising ICT01 Datafrom the EVICTION Study at ASCO 2024 Interim data from Phase I/II EVICTION study shows favorable safety profile and promising efficacy for ICT01 in combination...
'Les Voiles de l'Espoir' arrives in Monaco on the 19th of June
29 mai 2024 04h54 HE
|
Yacht Club de Monaco
TURIN, Italy, May 29, 2024 (GLOBE NEWSWIRE) -- Supporting children aged 8 to 14 from all backgrounds (France, Morocco, Israel, Luxembourg, Belgium, Switzerland, and other countries) in remission...
Burning Rock Reports First Quarter 2024 Financial Results
29 mai 2024 01h34 HE
|
Burning Rock Biotech Limited
Burning Rock Reports First Quarter 2024 Financial Results
CARGO Therapeutics to Participate in Upcoming Investor Conferences
28 mai 2024 08h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
28 mai 2024 08h00 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
28 mai 2024 06h30 HE
|
G1 Therapeutics
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 ADC
Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours
28 mai 2024 06h24 HE
|
Urteste S.A.
28 MAY 2024 PRESS RELEASE Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours Gdańsk, Poland – 28 MAY 2024, Urteste S.A. (Warsaw Stock...
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
24 mai 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024
23 mai 2024 02h00 HE
|
Burning Rock Biotech Limited
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024